+1 (800) 559-9921
Dear Fellow Scientists:
As we bid farewell to 2024, we’re excited to share our latest accomplishments. Our December newsletter highlights the significant strides we’ve made throughout this month and unveils exciting plans for the coming year. We invite you to join us in celebrating our achievements and envisioning a bright future!
Scroll down to read more!
Paving the Way to 2025: December’s Milestones
Pioneering Early Detection of Alzheimer’s with Custom Assays
MRMP is thrilled to have developed customized assays for AgenT in Paris, France, advancing early detection of Alzheimer’s disease. These assays leverage MRM technology for absolute quantitative analysis of both the plasma metabolome and proteome. Successfully transferred to Inovie in Marseille, these groundbreaking assays will soon be available to clients, marking a significant step forward in early Alzheimer’s detection. Proud to be part of this mission with AgenT and Inovie!
SysQuan Method for Human Proteome Quantitation Takes Center Stage!
We’re excited to announce that our latest method for absolute, system-wide quantitation (SysQuan) of the human proteome—developed using SILAC-labeled mice—has been published on BioaRxiv and presented by Dr. Borchers at the CFABS symposium series in Toronto, Montreal, and Vancouver. The CFABS events saw a record turnout of 600 attendees, marking a milestone in proteomics research.
Proud to contribute to advancing proteomics with SysQuan!
SSP 2024: Uniting Innovators in Structural Proteomics at MIT & Harvard’s Broad Institute
Founded by Dr. Evgeniy V. Petrotchenko and Christoph H. Borchers, the Symposium for Structural Proteomics (SSP) was held in the United States for the first time at the world-renowned Broad Institute of MIT & Harvard in Cambridge, MA.
With 250 attendees, the SSP 2024 brought together leaders in structural mass spectrometry, cryo-electron microscopy, computational structure prediction, and integrative modeling.
Topics Included: Crosslinking mass spectrometry- Labeling Approaches (HDX, FPOP)- Protein Interactome Mapping- Computational Approaches in Structural Proteomics- Intact and Top-Down Mass Spectrometry- Integrative Structural Biology- Emerging Methods.
To find out more about the organizers, speakers and the sessions addressed:
Kicking Off the New Year with Innovation: MRMP Europe is Fully Operational!
We are thrilled to announce that MRMP Europe (MRMPE) is now fully operational and prepared to provide cutting-edge proteomic assays. Our services focus on targeted proteomic analysis, leveraging the precision of internal standards to deliver highly accurate and reproducible results.
As part of this development, MRMPE, based in Russelsheim- Germany, has been successfully incorporated into MRMP, creating a unified platform that enhances our capabilities. This strategic connection bridges our operations between Europe and North America, enabling a global reach and the ability to deliver leading-edge services to our clients worldwide. With this integration, we are now equipped to take on a wide range of contracts, offering tailored solutions to meet the diverse needs of our clients in research, clinical applications, and biotechnology.
This milestone reflects our commitment to advancing proteomic analysis through innovation and excellence. We look forward to collaborating with researchers and organizations to achieve breakthrough results.
Combined Inhibition of MNK Signaling and BET Proteins Reveals TGM2 as a Novel Vulnerability in Melanoma
This study- conducted in collaboration with the Segal Cancer Proteomics Centre/Warren Y. Soper Clinical Proteomics Centre- explores how targeting MNK1/2 signaling and BET proteins can address resistance mechanisms in melanoma. The research highlights that this combined inhibition significantly disrupts tumor progression by exploiting vulnerabilities associated with TGM2, a key mediator in tumor adaptation and survival. This dual-target approach offers a promising therapeutic strategy for overcoming treatment resistance in melanoma cases.
Unlocking New Potential in Plasma Protein Quantitation!
We’re excited to share that our latest collaborative study with the Segal Centre Proteomics Centre/Warren Y. Super Clinical Proteomics Centre, MRMP, and Seer has been published in Analyst. This research demonstrates that by combining Seer’s advanced fractionation technology with MRMP’s 270 protein kit, we’ve achieved the absolute quantitation of twice as many plasma proteins!
This breakthrough offers new insights into proteomics, paving the way for more comprehensive and precise analyses in clinical research.
Read more about our findings and the potential for future advancements here: